Presentation

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells (Revascor™) in Patients With Chronic Heart Failure of Ischemic or Nonischem

Presenter: Kenneth M. Borow

January 22, 2013

REGISTER for free or LOG IN to view this content

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells (Revascor™) in Patients With Chronic Heart Failure of Ischemic or Nonischem

Heart Failure

Presentation

Cell Therapy 2013

Up Next

Presentation

SDF-1: Final Results of a Phase 1 Trial and Status of STOP-HF Study

Presenter: Marc S. Penn

January 22, 2013

More slides +

Presentation

Clinical Outcomes and Surrogate Efficacy Data for a Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells

Presenter: Kenneth Borow

January 22, 2013

Presentation

EXCELLENT Trial Design

Presenter: J?r?me Roncalli

January 22, 2013

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.